Evidence map›Paper›PMID 40394150›Full record

ArticleBritish journal of cancer2025

Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.

Roope A Kallionpää, Eija Martikkala, Pekka Haapaniemi, Sanna-Maria Karppinen, Pilvi Riihilä, Anne Rokka, Ilmo Leivo, Taina Pihlajaniemi, Sirkku Peltonen, Juha Peltonen

Abstract readComparative Study
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Roope A KallionpääCancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-7512-2980
Eija MartikkalaCancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.
Pekka HaapaniemiTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Sanna-Maria KarppinenECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
Pilvi RiihiläDepartment of Dermatology and Venereology, University of Turku, Turku, Finland.
Anne RokkaTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Ilmo LeivoCancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland.
Taina PihlajaniemiECM-Hypoxia Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
Sirkku PeltonenDepartment of Dermatology and Venereology, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-0990-1430
Juha PeltonenCancer Research Unit, Institute of Biomedicine, University of Turku, Turku, Finland. juhpel@utu.fi.ORCID http://orcid.org/0000-0002-5732-4167

Funding

Children's Tumor Foundation (CTF) 2023-01-006
6 · The paper itself

Abstract

backgroundCutaneous neurofibromas (cNFs) are the hallmark of the tumor-predisposition syndrome neurofibromatosis 1 (NF1). While cNFs are always benign, they markedly decrease quality of life in individuals with NF1. Understanding the differences between cNFs and the skin is essential for developing treatments for cNFs.

methodsWe collected 15 cNFs from four NF1 individuals and used mass spectrometry to compare the tumor tissue with the skin overlying each tumor. Data were analyzed based on Gene Ontology (GO) terms.

resultsThe expression patterns of the Schwann cell marker S100B and several keratins confirmed successful dissection of cNF tissue from the overlying skin. Hierarchical clustering showed extensive overlap between the tumor and skin samples in three out of four individuals, suggesting high overall similarity between the two tissue types. Based on the analysis of the GO terms, cNFs were associated with decreased expression of proteins related to cell proliferation, extracellular matrix remodeling, angiogenesis and cellular metabolism.

conclusionThe cNFs are relatively quiescent, consistent with their benign nature and limited growth potential. The development of pharmacological therapy for cNFs requires overcoming the high similarity between cNFs and the overlying skin. The present dataset can serve as a resource for future research on cNFs.

Indexed as

NeurofibromaNeurofibromatosis 1SkinSkin NeoplasmsAdultFemaleHumansMaleMass SpectrometryMiddle AgedS100 Calcium Binding Protein beta SubunitS100 Calcium Binding Protein beta Subunit

Identifiers

PMID40394150
PMCPMC12322300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.